PURE Bioscience, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-2.4M | $-3.4M | $-4.0M | $-3.5M | $-2.3M | $4.0K | $-6.6M | $-7.4M |
| Depreciation & Amortization | $2.0K | $148.0K | $117.0K | $213.0K | $172.0K | $192.0K | $241.0K | $285.0K |
| Depreciation | $2.0K | $148.0K | $117.0K | $146.0K | $97.0K | $104.0K | $106.0K | $106.0K |
| Amortization | — | — | — | — | $75.0K | $75.0K | $135.0K | $179.0K |
| Stock-Based Compensation | $147.0K | $214.0K | $324.0K | $567.0K | $841.0K | $787.0K | $2.4M | $2.4M |
| Net Cash from Operating Activities | $-2.0M | $-2.5M | $-3.3M | $-2.4M | $-1.2M | $669.0K | $-3.0M | $-3.9M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | $33.0K | $81.0K | $521.0K | $58.0K | $7.0K | $19.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | $-33.0K | $-81.0K | $-521.0K | $-58.0K | $-13.0K | $-34.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $2.0M | $1.8M | $1.0M | $3.5M | $239.0K | $2.8M | $2.6M | $3.1M |
| Net Change in Cash | $-15.0K | $-746.0K | $-2.3M | $1.0M | $-1.4M | $3.4M | $-453.0K | $-789.0K |
| Free Cash Flow | — | — | $-3.3M | $-2.5M | $-1.7M | $611.0K | $-3.0M | $-3.9M |